Immuno 2024

25 - 26 April 2024 | London, UK

A two-day event packed with leading speakers, research and cutting-edge presentations on the latest advancements in the discovery & development of cancer immunotherapies.

Presentation Speaker
Overview Advances in Immuno-Oncology Targets & Cell Types in Immuno-Oncology

Explore Immuno 2024: Unlocking Future Insights in Immuno Research

Join 400+ leaders, experts and researchers at Immuno 2024, connecting pharmaceutical & biotech representatives as well as academia for high-level discussions on the latest innovations in immune-oncology discovery & therapeutics development. Immuno 2024 features our ever popular 9th Annual Advances in Immuno-Oncology Congress and the 2nd Annual Targets & Cell Types Congress is attended by over 400 senior level attendees in London to network, debate and discuss the industry’s pressing challenges & opportunities; fostering partnerships & collaborations in the field. Do not miss out on attending these events to stay at the forefront of the latest advancements pushing the immune-oncology industry forward – from the discovery & development of cell & gene, antibody & combination therapies, through to the utilisation of omics techniques and technologies in IO as well as novel target identification & validation strategies. New to the agenda is the introduction of the Innovation & Collaboration track showcasing emerging biotechs & pioneering academic s pin off entering the market.

9th Annual Advances in Immuno-oncology Congress

A two-day event packed with leading speakers, research and cutting-edge presentations on the latest advancements in cancer immunotherapy – from cell, antibody-based and combination therapies through to the application of spatial technologies in immuno-oncology and utilising small molecules as immuno-oncology targets.

  • Gain a forward-looking perspective on the opportunities and challenges impacting market growth in immuno-oncology. Our congress brings together immuno-oncology experts across five tracks to provide a comprehensive look at the key trends in this industry, from therapeutic strategies and modelling through to the latest clinical data.
  • Gain invaluable insights into IO clinical trials: design, patient engagement & data-driven IO therapy development, from implementation of successful trial design strategies, through to the use of standardised reporting guidelines and leveraging digital technologies and AL/ML in clinical trial management & patient selection. 
  • Discover the promise of multi-omics guided immune-oncology. Take a deep dive into the utilisation of spatial technologies in immune-oncology, single cell multi omics in IO and genetic analysis technologies for IO research. 

Agenda at a Glance


Day One, Track 1: Discovery & Development: Cell & Combination Therapies

Day One, Tack 2: Biomarkers, Spatial Biology & Precision Medicine In Immuno-Oncology

Day One, Track 3: Advancing IO Clinical Trials: Design, Management, Operations & Digitalisation

Day Two, Track 1: Discovery & Development: Intratumoral Immunotherapies & Antibody Therapies

Day Two, Track 2: Large & Small Molecule-Based Preclinical, Clinical & Translational

2nd Annual Targets & Cell Types in Immuno-Oncology Congress 2024

Join thought-leaders in London to take a deep dive into the recent advances and latest approaches to novel targets & cell types in immune-oncology. From emerging target identification & validation methods and strategies through to latest development 
in various cellular therapies and immune cell engagement & activation. Do not miss our on participating in engaging panel & roundtable discussions, workshops and enjoy networking during the refreshment breaks facilitating the establishment of collaborations in the field.

  • Discuss the latest innovations in novel targets & target validation in immuno-oncology. Presentations will delve into AI-based approaches for target identification & validation; new technological approaches such as screening and CRISPR and new modalities approaches.
  • Discover collaborative solutions to novel cell types to develop effective IO therapies. Delve into case studies in the utilisation of various cellular therapies such as TILs, suppressor & myeloid cells, preclinical tumour models and bispecific antibodies activating the immune system.

Agenda at a Glance


Day One, Track 1: Novel Targets in Immuno-oncology: Identification & Validation

Day Two, Track 1: Emerging Cell Types to Enhance the Development of Novel Therapeutics

What to Expect

400

leading pharma, biotech & academic delegates

20
hours of presentations, discussions & interactive content
9
hours of networking breaks, including speed networking & refreshments
150
hours of pre-arranged 1-2-1 meetings, facilitating business growth
Interactive Presentations
Exhibition Hall
Networking Drinks
Poster Display
Event App Swapcard

Networking & knowledge-sharing is at the heart of what we do. Alongside the innovative programme, attendees can engage in a variety of event features and make the most of participation in a range of experiences

  • Engaging Thought Leadership

    Over 80 dynamic interactive discussions, roundtables, and presentations curated with insights from top industry leaders and experts
  • Global Technological Showcase

    An international exhibition showcasing cutting-edge technologies and services from leading providers in the scientific field.
  • Networking Emphasis

    Unparalleled networking opportunities, including speed networking sessions, a vibrant drinks reception, and informal gatherings to foster meaningful connections
  • Innovative Poster Displays

    Inspiring poster displays and presentations unveiling the latest breakthroughs from emerging biotech, pharma, and academic institutions

Companies Represented Include

Meet Our Expert Speakers

Immuno 2024 again brings together a panel of prominent leaders and scientists, sharing new case studies, innovative, data and industry outlooks.

Below are some of our featured speakers:

Eleni Chantzoura
Director of Discovery,
MiNK Therapeutics
Mani Mudaliar
Target Analyst Director,
Exscientia
Miguel Gaspar
Director,
Astrazeneca
Sari Pesonen
Chief Scientific Officer,
Valo Therapeutics
Xi Zhao
Head, Computational Oncology, Research and Development | Senior Principal Scientist, Genomics Research Center,
AbbVie

All Speakers

Adam Drake
Senior Director of in vivo Pharmacology,
ichnossicences.com
Alastair Corbin
Principal Scientist,
Pathios Therapeutics
Alexandra Sevko
Director, Translational Research,
Prokarium
Amit Grover
Scientist,
AZ
Anette Sundstedt
Principal Scientist,
Alligator Bioscience
Angelica Loskog
CEO,
Lokon Pharma
Barbara Lösch
Head of Technology and Innovation,
Medigene Immunotherapies GmbH
Benoit Van den Eynde
Professor,
Ludwig Institute for Cancer Research, Oxford University / VOLT
Chris Holland
Senior Manager, Research - Experimental Immunology.,
Immunocore
Christine Rothe
CDO,
iOmx Therapeutics AG
Colette Johnston
VP Head of Product Platform Research,
Enara Bio
Cynthia Chauvin-Fleurence
Associate Principal Scientist,
AstraZeneca
Dan Crowl
CEO,
Remedy Biologics Ltd
Deepak B
Assistant Professor,
University of South Carolina School of Medicine
Dhiman Ghosh
Lab Head|Senior Principal Scientist,
Sanofi
Emiko DESVAUX
Principal Translational Medicine Scientist,
Sanofi
Eric O'Neill
Professor of Cell & Molecular Biology,
Centre for Medicines Discovery
Jens Vindahl Kringelum
Vice President, AI & Innovation,
Evaxion Biotech
Johan Pijnenborg
CEO,
GlycoTherapeutics B.V.
John Maher
CSO,
Leucid Bio
John Rossi
Vice President,
CARGO Theraputics
John Stephen Bridgeman
Director,
Instil Bio
Jon Moore
CSO,
Epitopea Limited
Jonathan Kwok
Chief Executive Officer,
Infinitopes
Kenneth Crook
Head of Translational Medicine,
Engimmune Therapeutics
kieran whelton
Data scientist,
AbbVie
Klaus Okkenhaug
Professor of Immunology,
University of Cambridge
Laurène Pousse
Scientist and research project leader,
Roche
Livija Deban
CSO,
Prokarium
María Laura García Bermejo
Scientific Director,
Ramon y Cajal Health Research Institute (IRYCIS)
Maria Stella Sasso
Senior Principal Scientist,
Akamis Bio Ltd
Mark Cragg
Professor of Experimental Cancer Biology,
University of Southampton
Martin Miller
Senior Director,
AstraZeneca
Massimiliano Mellone
Senior Scientist,
astrazeneca
Mini Bharathan
Senior Vice President, R&D & Translational Medicine,
Arovella
Natalia Venetz
Scientist,
Molecular Partners AG
Nisit Khandelwal
CTO,
iOmx Therapeutics
Øystein Rekdal
Chief Executive Officer,
Lytix Biopharma
Pedro Correa de Sampaio
CEO,
Neobe Therapeutics
Philip Arlen
CEO,
Precision Biologics
Philip Beer
Chief Scientific Officer,
Step Pharma
Pierre Dönnes
VP,
Strike Pharma AB
Pini Tsukerman
Chief Scientific Officer,
Nectin Therapeutics
Rahul Roychoudhuri
Professor,
University of Cambridge
Raj Mehta
Chief Executive Officer,
Adendra Therapeutics
Rick Kamps
NGS labmanager,
University of Maastricht Translational Genomics
Robert de Jonge
VP Head of Corporate Development,
Mestag Therapeutics
Robyn Broad
Principal Scientist,
Adaptimmune
Russell LaMontagne
CEO,
Boston Immune Technologies and Therapeutics, Inc.
Sarah-Kim Friedrich-Becker
Senoir Principal Scientist,
Abalos Therapeutics GmbH
Simon Krah
Associate Director,
Merck Healthcare KgaA
Simon Barry
Executive Director,
AstraZeneca
Sophia Karagiannis
Professor of Translational Cancer Immunology and Immunotherapy,
King's College London
Stefan Zielonka
Professor & Global Head of Antibody Discovery and Protein Engineering,
Merck Healthcare KGaA & Technische Universität Darmstadt
Steve Thorne
CSO,
Western Oncolytics
Sylwia Marshall
VP, Translational Sciences,
invoX Pharma
Thomas Bogenrieder
Chief Medical Officer,
Abalos Therapeutics
Thorsten Ross
VP Preclinical Research & Translation Strategy,
Affimed
Timo Van den Berg
Senior Director Immuno-Oncology,
Byondis
Volker Huppert
Chief Development Officer,
Glycostem Therapeutics
William Jackson
Senior Scientist,
Bioarchitech Ltd
Yi-Ru Yu
Senior Scientist,
Pilatusbio
Yong-Jie Lu
Professor in Molecular Oncology,
Queen Mary University of London

Interested in Sponsoring?

Oxford Global’s range of sponsorship opportunities are highly effective in enabling market immersion and visibility, with direct access to clients and potential customers.

Learn more

Latest Resources

New Multi-Omic AI-Driven Initiative for Immuno-Oncology Biomarker Development

The team aims to establish a consortium of cancer centres to join the project of developing biomarkers from multi-omic analysis.

Uncovering Mechanisms of Immunotherapy Response & Resistance with Single Cell & Spatial Multiomics

Discover how 10x Genomics' spatial technologies are revolutionising the study of immunotherapies in solid tumors

Decoding the Language of Tumor Immune Microenvironment: A Deep Dive into Spatial Biology Techniques

Immuno by Oxford Global will delve into the fascinating world of spatial biology techniques and their role in decoding the language of the tumour immune microenvironment.

Plan Your Visit

Novotel London West

1 Shortlands,
Hammersmith International Ctre,
London, W6 8DR

Just minutes from three of London's main tube lines (Piccadilly, District and Hammersmith & City) and located in the heart of Hammersmith; Novotel London West is ideally located for trips to Westfield London, Harrods & Kensington High Street. Also conveniently located to Heathrow Airport with excellent road and rail links to the rest of the UK. This large and modern hotel offers on-site parking (chargeable), fitness suite and complimentary Wi-Fi throughout.

By Air

London Heathrow Airport - Novotel London West is accessible from Heathrow via the Underground on the Piccadilly Line – fares cost around £5 into Central London. A taxi from the airport will take approximately 20 minutes and will cost around £30 - £40.

London Gatwick Airport - The Gatwick Express runs every 15 mins - take it to Victoria station, and then get the District line to Hammersmith (about 15 mins). A taxi from the airport will take around 60 mins and cost between £65 - £80.

By Underground & Bus

Hammersmith Underground Station is adjacent to the hotel (3 minutes walk) with access to the Piccadilly, District and Hammersmith & City Lines. When exiting Hammersmith station, turn right and walk across the bus station. Cross over the roads using the island and keep on the right-hand side of Hammersmith Road. Continuing walking for 2 mins, and the hotel is accessible via stone steps.

For buses in central London, take route numbers 9 and 10. The main coach station (London Hammersmith) is 3 minutes walk away.

By Rail

The closest National Rail train station is Kensington Olympia (20 minutes walk).

By Car

Leave the A4 at the Hammersmith turning and proceed along Hammersmith Bridge Road to the large roundabout underneath the flyover. Take the fifth exit off the roundabout. Then turn left into Shortlands - the main hotel entrance and parking will be on your left-hand side.

Parking

Novotel London West offers over 240 on-site car parking spaces (charged per hour for residents parking). For further information including a map and full directions, please visit: www.novotel.com/gb/hotel-0737-novotel-london-west/index.shtml

Wednesday 24th April 2024 – £192 including VAT and breakfast

Thursday 25th April 2024 – £192 including VAT and breakfast

*Please note: £10 supplement is applicable for double occupancy

 

Should you wish to book a room, please email help@oxfordglobal.co.uk. The final cut-off date to book bedrooms is Thursday 28th March 2024 – any bookings after this date are subject to availability and rates. Please note that any cancellations within 14 days prior to arrival are subject to cancellation charges.

We are closely monitoring the official guidance from health authorities, local governments, and the World Health Organization in order to support the health and well-being of our global community. The health and safety of our staff, customers and clients remains our number one priority.

As we continue to move forward with hosting our events in-person in 2024, we’ve added a series of Health & Safety guidelines and precautions in order to prepare for event safety. We carry out risk assessments for all our events to evaluate fundamental considerations and how to cover multiple risk scenarios.

Oxford Global has learned that third-party companies (recently EHotel Services, Business Travel Management/btravelmanagement and Exhibitors Hotel Reservations Services) are targeting conference attendees with a fraudulent hotel booking scheme.

Please note that none of these third-party companies are associated with Oxford Global in any way, nor have Oxford Global authorised them to use their names or trademarks on information they send out to attendees.

If you are contacted by a third-party company by phone or email using Oxford Global’s name or the name of Immuno 2024 and offering accommodation services, we urge exhibitors and attendees to proceed with extreme caution before signing anything sent by these companies or entering into any conversation or replying to any emails sent from these third-party companies.

Register Your Interest

Submit your details and a member of our team will be in touch